Martina M.D. Flammer Sells 6,172 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 6,172 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.64, for a total value of $392,786.08. Following the sale, the insider now directly owns 101,549 shares in the company, valued at $6,462,578.36. This trade represents a 5.73 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Martina M.D. Flammer also recently made the following trade(s):

• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The stock was sold at an average price of $65.91, for a total value of $220,403.04.

Insmed Stock Down 0.7 %

INSM opened at $65.25 on Friday. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The business has a 50-day moving average of $71.23 and a two-hundred day moving average of $72.44. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market capitalization of $11.67 billion, a price-to-earnings ratio of -11.76 and a beta of 1.12.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analysts’ expectations of $93.36 million. The business’s revenue for the quarter was up 18.1% compared to the same quarter last year. During the same period last year, the firm posted ($1.10) EPS. On average, research analysts expect that Insmed Incorporated will post -5.44 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Victory Capital Management Inc. increased its stake in Insmed by 672.7% during the second quarter. Victory Capital Management Inc. now owns 147,140 shares of the biopharmaceutical company’s stock worth $9,858,000 after acquiring an additional 128,098 shares during the last quarter. Private Advisor Group LLC purchased a new position in Insmed in the second quarter valued at approximately $575,000. Los Angeles Capital Management LLC acquired a new position in Insmed during the second quarter valued at approximately $258,000. ClariVest Asset Management LLC purchased a new stake in Insmed during the second quarter worth approximately $738,000. Finally, American Century Companies Inc. increased its position in shares of Insmed by 7.5% in the second quarter. American Century Companies Inc. now owns 755,271 shares of the biopharmaceutical company’s stock worth $50,603,000 after acquiring an additional 52,647 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on INSM shares. Bank of America raised their price target on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. JPMorgan Chase & Co. lifted their target price on shares of Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research report on Friday, November 22nd. HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. Finally, Truist Financial restated a “buy” rating and set a $105.00 price objective (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.